Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.

Selinexor–dexamethasone combo shows activity against refractory multiple myeloma

16 Nov 2019

The combination of oral selinexor plus dexamethasone appears to induce response in patients with triple-class refractory myeloma, according to data from the second part of the phase II STORM* study.

A total of 123 patients received oral selinexor (80 mg) plus dexamethasone (20 mg) twice weekly. All of them had disease refractory to at least one proteasome inhibitor, one immunomodulatory agent and daratumumab. The median age of the population was 65 years, and the median number of previous regimens was seven. More than half of the patients (53 percent) had high-risk cytogenetic abnormalities.

Twenty-six percent of the population achieved the primary outcome of a partial or better response (including two stringent complete responses), while 39 percent showed minimal response or better. The median duration of response was 4.4 months.

The median progression-free survival was 3.7 months (95 percent confidence interval [CI], 3.0–5.3), and the median overall survival (OS) was 8.6 months (95 percent CI, 6.2–11.3). OS was more favourable in the subgroups of patients with a partial response or better and those with a minimal response or better (median, 15.6 months in both).

In terms of safety, commonly reported adverse events (AEs) were mild-to-moderate fatigue, nausea and decreased appetite. Twenty-five percent of patients developed grade 3 AEs, and none had grade 4 AEs. Thrombocytopaenia occurred in 73 percent of the patients, leading to bleeding events of grade 3 in six patients.

The present data establish the activity of selinexor with dexamethasone. Researchers pointed out that they used a regimen with a high dose of selinexor to achieve rapid disease control, given the small window of opportunity to prevent further illness and death owing to the fast progression of penta-exposed, triple-class refractory myeloma.

*Selinexor Treatment of Refractory Myeloma

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.